NASDAQ:BNR

Burning Rock Biotech Q2 2025 Earnings Results & Report

Burning Rock Biotech logo
$13.07 +0.57 (+4.56%)
Closing price 04:00 PM Eastern
Extended Trading
$13.30 +0.23 (+1.78%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Burning Rock Biotech reported Q2 2025 earnings on September 8, 2025. The company reported EPS of -$0.15, while revenue was $20.74 million.

Earnings Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call
6:00 AM ET

Burning Rock Biotech EPS Results

Actual EPS
-$0.15
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Burning Rock Biotech Revenue Results

Actual Revenue
$20.74 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

Burning Rock Biotech Q2 2025 Earnings FAQ

Burning Rock Biotech (NASDAQ:BNR) reported earnings of -$0.15 per share for Q2 2025. The report was announced on Monday, September 8, 2025.

Burning Rock Biotech reported revenue of $20.74 million for Q2 2025.

Burning Rock Biotech Earnings Headlines

Burning Rock Biotech (BNR) versus Its Competitors Critical Analysis
You missed yesterday's deadline…
In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.tc pixel
Burning Rock Biotech (BNR) Projected to Release Earnings on Tuesday
See More Burning Rock Biotech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Burning Rock Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Burning Rock Biotech and other key companies, straight to your email.

About Burning Rock Biotech

Burning Rock Biotech (NASDAQ:BNR) is a precision oncology company that develops and provides next-generation sequencing tests for cancer. Its testing uses tissue and blood samples to help inform treatment decisions, monitor disease and support cancer research.

The company also provides research and clinical-trial services to pharmaceutical companies, including support for the development of cancer therapies and diagnostic tests. Burning Rock is headquartered in Guangzhou, China, and its business primarily serves the Chinese healthcare and life sciences markets.

Founded in 2014, Burning Rock focuses on applying genomic testing to cancer care, including the development of tests for treatment selection and disease monitoring.

View Burning Rock Biotech Profile